Head-to-head · Cost-Efficiency Index
DoctorAdam vs Direct Meds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
DoctorAdam
Shoppers who want a needle-free oral GLP-1 with named prescribers, in the 47 states DoctorAdam actually serves.
Visit DoctorAdamDirect Meds
Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Visit Direct MedsThe verdict
DoctorAdam takes it, leading the Cost-Efficiency Index 74 to 71. DoctorAdam is a Shopify-storefront telehealth company selling compounded oral (sublingual) and injectable semaglutide and tirzepatide plus NAD+/glutathione add-ons, prescribed by a named roster of six MD/NP prescribers. Direct Meds still earns a C — Needle-averse shoppers who want a sublingual route on either molecule and will pay above the going rate for it, having accepted a three-month supply as the smallest unit sold.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs DoctorAdam.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | DoctorAdam | Direct Meds |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 71/100 |
| Semaglutide / mo | $129/mo (starting dose, compounded oral) | $249/mo (sublingual, 90-day supply billed monthly) |
| Tirzepatide / mo | $199/mo (starting dose, compounded oral) | $299/mo (sublingual, 90-day supply billed monthly) |
| Semaglutide / yr (modeled) | $1,548 | $2,988 |
| Tirzepatide / yr (modeled) | $2,388 | $3,588 |
| Coverage | 44 states | Not disclosed |
| Oral / sublingual | Yes | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #58 | #64 |
DoctorAdam
74/100Where the value is
- Names six actual prescribers with credentials — unusually transparent for a Shopify-based storefront
- Needle-free oral tablet option for both semaglutide (from $129) and tirzepatide (from $199)
- Flat 'no hidden fees' pricing framing, with free 2-3 business day shipping
The tradeoffs
- The homepage claims 'Delivery Across All 50 States' but the site's own FAQ state list is 47 states plus DC — New Jersey, Mississippi, and Alaska are excluded
- Injectable dose-tier pricing could not be verified live in this pass (repeated 429 errors on the product pages); only the oral 'from' price is confirmed
Direct Meds
71/100Where the value is
- Sublingual AND injection on BOTH molecules — four GLP-1 SKUs, the widest formulation range of any provider in this ranking
- Every price is published per SKU in a public shop, with no quiz, intake or email capture in front of it
- Each product page prints a per-day equivalent beside the monthly rate ($8.03/day at $249), which is unusually concrete for this category
The tradeoffs
- $249/mo sublingual is well above this ranking's ~$144 median, and the injection route is $297 — the cheapest thing here is dearer than most rows' headline price
- The only purchasable option on every product page is a 90-DAY SUPPLY billed monthly, so three months is the smallest unit sold — there is no month-to-month rate to compare against the rows beside it
Regulatory note: the FDA issued a warning letter to directmeds.com, Inc. dba DirectMeds in September 2025. We still list and link to Direct Meds; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.